Investigators sought to define the clinical association of clinical and imaging definitions of synovitis in patients with SLE with musculoskeletal symptoms.
Results from a phase 2 study suggest that ustekinumab might be an effective therapy in systemic lupus erythematosus.
Therapeutic drug monitoring may be useful to help clinicians assess nonadherence in patients with SLE.
Patient-reported outcomes are independent predictors of mortality in systemic lupus erythematosus.
Vaccination rates in patients with systemic lupus erythematosus improved significantly after the implementation of a multifaceted intervention at a rheumatology practice.
The use of validated disease activity and damage metrics is important in the assessment of SLE.
Prolonged antimalarial therapy and persistent creatine phosphokinase elevation resulted in an increased risk for abnormal brain natriuretic peptide and cardiac troponin.
The risk factors for accelerated cardiovascular disease among young women with SLE remain unclear, with multiple studies producing conflicting results.
Patients with systemic lupus erythematosus have a high prevalence of subclinical myocardial injury, as evidenced by raised high-sensitive troponin levels.
Patients with early SLE had higher rates of unexplained fever than those with SLE-mimicking conditions.